We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
DHR.MX

Price
3733.57
Stock movement down
-127.75 (-3.31%)
Company name
Danaher Corporation
Exchange
(MX
,
Currency
MXN
)
Sector
Healthcare >
Diagnostics & Research
Market cap
2696.66B
Ent value
2722.94B
Price/Sales
127.77
Price/Book
54.04
Div yield
-
Div growth
-
Growth years
-
FCF payout
23.58%
Trailing P/E
641.60
Forward P/E
-
PEG
-
EPS growth
11.27%
1 year return
-8.68%
3 year return
-14.63%
5 year return
2.14%
10 year return
11.51%
Last updated: 2025-04-12

DIVIDENDS

DHR.MX does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E641.60
Price to OCF418.28
Price to FCF528.55
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales127.77
Price to Book54.04
EV to Sales129.02

FINANCIALS

Per share

Loading...
Per share data
Current share count722.28M
EPS (TTM)5.81
FCF per share (TTM)7.05

Income statement

Loading...
Income statement data
Revenue (TTM)21.11B
Gross profit (TTM)12.54B
Operating income (TTM)4.54B
Net income (TTM)4.20B
EPS (TTM)5.81
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)59.41%
Operating margin (TTM)21.49%
Profit margin (TTM)19.91%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.37B
Net receivables3.30B
Total current assets9.61B
Goodwill40.80B
Intangible assets19.55B
Property, plant and equipment8.69B
Total assets78.56B
Accounts payable1.65B
Short/Current long term debt0.00
Total current liabilities6.70B
Total liabilities28.65B
Shareholder's equity49.90B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)6.45B
Capital expenditures (TTM)1.34B
Free cash flow (TTM)5.10B
Dividends paid (TTM)1.20B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity8.42%
Return on Assets5.35%
Return on Invested Capital6.35%
Cash Return on Invested Capital7.71%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3670.00
Daily high3733.57
Daily low3670.00
Daily Volume2K
All-time high7104.69
1y analyst estimate-
Beta0.88
EPS (TTM)5.81
Dividend per share-
Ex-div date27 Dec 2019
Next earnings date21 Apr 2025

Downside potential

Loading...
Downside potential data
DHR.MXS&P500
Current price drop from All-time high-47.45%-14.41%
Highest price drop-53.55%-56.47%
Date of highest drop1 Nov 20239 Mar 2009
Avg drop from high-13.27%-11.07%
Avg time to new high6 days12 days
Max time to new high849 days1805 days
COMPANY DETAILS
DHR.MX (Danaher Corporation) company logo
Marketcap
2696.66B
Marketcap category
Large-cap
Description
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Employees
61000
Investor relations
-
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best ...
April 13, 2025
We recently published a list of Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks that Jim Cramer...
April 11, 2025
Andvari Associates, an investment management firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter the fund returned 7.2% net of fees...
April 10, 2025
We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks with ...
April 8, 2025
Last week, the market was shaken by significant events, including President Trump's announcement of sweeping tariffs, sparking fears of a global economic downturn. Danaher (NYSE:DHR) experienced an 11...
April 5, 2025
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
April 4, 2025
Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities exper...
April 3, 2025
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Oracle Corp. (ORCL) and Merck & Co., Inc. (MRK).
April 1, 2025
We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other be...
April 1, 2025
We recently published a list of Top 10 Stocks to Buy According to Akre Capital Management. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other top...
March 29, 2025
Next page